Year: 2024
Type: dissertation
Abstract: N-methyl-D-aspartate receptor (NMDAR) is an ionotropic glutamate receptor that plays an important role in brain development, learning and memory. NMDARs are encoded by GRIN genes (GRIN1, GRIN2A-D, and GRIN3A-B). Rare de novo mutations in one of the GRIN genes lead to GRIN disorder, a neurodevelopmental disorder with a broad spectrum of life-threatening symptoms. Most pathogenic variants are missense heterozygous mutations that can lead to over- or under-activation of NMDAR. Such variants are classified as gain-of-function or loss-of-function variants, respectively. As a result, pharmacological interventions directly targeting NMDAR often show mixed results in patients. Development of gene-based therapies is desired. A functional NMDAR is a heterotetrametric complex consisting of two obligatory GluN1 subunits encoded by GRIN1 gene. The other two subunits are a combination of any of the GluN2 or GluN3 subunits. We hypothesize that delivery of exogenous GRIN1 gene is beneficial for patients with missense GRIN1 variants regardless of the classification. The exogenous GRIN1 gene will lead to excess expression of functional GluN1 proteins that competes with variant proteins for the assembly into NMDARs. As a result, more NMDARs function normally. To test our hypothesis, we designed and developed genetic constructs containing a V5-tagged human GRIN1 cDNA of the GluN1-1a isoform (hGRIN1) for AAV transfer. We used two different promoters that drive ubiquitous (hGAPDH) or neuron-specific (hSYN1) expression. The constructs are packaged into an AAVHSC that can cross the blood brain barrier and transduce neurons and glial cells. We generated two mouse models possessing the equivalent GRIN1 patient variants, the Grin1Q536R/+ and Grin1Y647S/+ mice. Electrophysiological studies reveal that, remarkably, AAVHSC-delivered hGRIN1 showed significantly improved NMDAR-mediated synaptic transmission and restored long-term potentiation (LTP) in the hippocampus of both mouse models. For systemic transduction, we administered the vectors intravenously (i.v.). hGRIN1 expression was detected at mRNA and protein levels in the brain of Grin1Q536R/+ mice four- and twenty-week post i.v. injection. The expression was dose-dependent and preliminary behavioural improvement was observed. In summary, our strategy has translational potential for clinical applications and may serve as a novel one-time treatment for patients with pathogenic GRIN1 variants.
Source: TSpace (University of Toronto)
Author: Yan, Yuanye
Institution: University of Toronto
Language: English
Subfield: Genetics
Domain: Life Sciences
Keywords: gene replacement therapy, NMDA receptor, GRIN1, adeno-associated virus vectors, missense mutations, gain-of-function mutations, loss-of-function mutations, synaptic transmission, long-term potentiation, hippocampus, mouse model, neurodevelopmental disorders, blood-brain barrier penetration
Open Access status: green
OpenAlex ID: W7226056136
